The AI-Ready Lab Gets Smaller: Unchained's New Tool Tackles a Big Problem

PLEASANTON, CA – July 07, 2026 – The path to a new biologic or gene therapy is paved with groundbreaking science, but it's also riddled with mundane, time-consuming hurdles. For every eureka moment, there are countless hours of laborious, manual work. One of the most notorious of these productivity sinks is buffer exchange—a fundamental process of swapping the liquid medium a biologic sample resides in. It's a critical step for formulation, purification, and concentration, yet it has remained stubbornly manual and slow. Today, Unchained Labs made a direct assault on this bottleneck with the launch of Lil' Tuna, a compact, fully automated buffer exchange system designed not just to speed up a single task, but to rewire a core piece of the modern research workflow.

A Crowded Pond with a Niche to Fill

The market for bioprocessing tools is anything but empty. The global desalting and buffer exchange market was valued at over $1.2 billion in 2024 and is projected to nearly quadruple by 2032, driven by the explosive growth in biopharmaceuticals. Industry giants like Sartorius, Merck Millipore, and Cytiva offer a range of solutions, from centrifugal concentrators and tangential flow filtration (TFF) systems to specialized chromatography columns. These technologies have served the industry for years, but each comes with trade-offs in scalability, hands-on time, and suitability for high-throughput screening.

Unchained Labs has been methodically carving out its territory in this space. Its existing portfolio already includes Big Tuna, a high-throughput workhorse for plate-based buffer exchange, and Unagi, a benchtop system for processing a smaller number of individual samples. With Lil' Tuna, the company isn't just launching another product; it's executing a strategic pincer movement. The new system integrates the core strengths of its predecessors—the plate-based throughput of Big Tuna and the single-sample flexibility of Unagi—into a single, compact benchtop instrument. This hybrid approach targets a specific, unmet need: the lab that requires both high-volume screening capabilities and the agility to process a handful of precious, one-off samples without investing in multiple large-footprint machines. It’s a solution designed for the dynamic, often unpredictable, reality of R&D.

Under the Hood: Engineering for Efficiency and Recovery

At the heart of Lil' Tuna is the same pressure-based Ultrafiltration/Diafiltration (UF/DF) technology that powers its larger siblings. The system applies controlled pressure (up to 60 psi) to samples held in specialized 96- or 24-well plates, or in individual consumables called Unas. This pressure gently forces the existing buffer and small molecules through a semi-permeable membrane while retaining the much larger, high-value biomolecules. To prevent sample concentration at the membrane surface—a common issue that can slow filtration and damage proteins—the system employs gentle, automated mixing.

The critical metric in any buffer exchange process is sample recovery. Losing even a small percentage of a novel antibody or a complex viral vector can be a significant setback, both scientifically and financially. Here, Unchained Labs makes a bold claim: a sample recovery of ≥96%. This high rate of return is achieved by minimizing non-specific binding through the use of regenerated cellulose membranes and by eliminating manual transfer steps where sample loss often occurs. For researchers working with minute quantities of cutting-edge therapeutics, this level of efficiency isn't just a convenience; it's a necessity.

The system's versatility is a key part of its design philosophy. A lab can run a full 96-well plate for a formulation screen in the morning and then process six individual, high-volume samples in the afternoon on the same device. This flexibility streamlines resource allocation and makes advanced automation accessible to a broader range of lab sizes and budgets.

From Manual Labor to Intelligent Workflow

The most profound impact of Lil' Tuna may not be in its hardware, but in how it changes human workflow. "Buffer exchange has always been one of those steps that kills a scientist's momentum," noted Krystin Schmidt, VP of Marketing at Unchained Labs, in the company's announcement. The process traditionally involves constant babysitting, whether it's managing dialysis bags, loading and unloading centrifuges, or monitoring cartridge-based systems. By fully automating the entire cycle—from initial concentration to final volume adjustment—Lil' Tuna effectively gives back hours of a researcher's day.

This reclaimed time allows highly trained scientists to move away from repetitive manual labor and focus on what they do best: designing experiments, analyzing data, and driving discovery. Furthermore, automation brings a level of consistency and reproducibility that is difficult to achieve manually, reducing variability and strengthening the integrity of experimental data. As one industry analyst commented, this type of tool is less about replacing scientists and more about empowering them to operate at the top of their license.

However, the true forward-looking feature is Lil' Tuna's native integration with Stuntman, Unchained's AI-driven automation platform. This elevates the system from a standalone tool to an intelligent node in a connected laboratory ecosystem. The integration enables a "seamless handoff into formulation screening, stability characterization and other downstream workflows." In practice, this means a plate of newly buffer-exchanged samples can be automatically transferred by a robotic arm to another instrument for analysis, with all process data and sample information flowing digitally. This eliminates data entry errors and creates a cohesive, end-to-end research pipeline, dramatically accelerating the cycle time from idea to insight.

The Unchained Strategy: Building the Lab of the Future

The launch of Lil' Tuna is a clear reflection of Unchained Labs' overarching mission: to help biologics and gene therapy researchers "break free from tools that just don't cut it." The company has built its brand on identifying and solving specific, high-impact bottlenecks with thoughtfully designed, automated solutions. By focusing on the unique and demanding needs of biologics and gene therapy—where sample stability and integrity are paramount—the company has positioned itself as a key enabler in one of the most promising fields of medicine.

Lil' Tuna is more than an incremental product update; it's a building block for the AI-enabled lab of the future. The emphasis on a compact footprint, robotic accessibility, and deep software integration signals a vision where the lab is not a collection of siloed instruments but a holistic, intelligent system. Schmidt's assertion that the system is a "perfect fit for the next generation of AI-enabled labs" is not just marketing hyperbole; it is a statement of strategic intent. Unchained Labs is betting that the future of progress lies in creating these interconnected, automated environments, and with Lil' Tuna, it has just supplied another critical piece of that puzzle.